Recent Updates
Recently added Catalysts

Unfractionated heparin

Phase 3

Submassive Pulmonary Embolism | Small molecule | Other |Boston Scientific Corporation|Last Updated: Jul 19, 2021

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment59
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01166997ULTrasound Accelerated ThrombolysIs of PulMonAry EmbolismPHASE3 COMPLETED 59Jul 1, 2010May 1, 2013Jul 19, 202110 Germany, Switzerland
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Reduction of RV/LV Ratio
24 hours

Change in the end-diastolic RV/LV ratio from baseline to 24 hours by echocardiography.

Major Bleeding and Intracranial Bleeding at 30 Days.
30 days

Bleeding will be classified as major if it is associated with a fall in the hemoglobin level of at least 2.0 g/dl, transfusion of ≥ 2 units of red blood cells, or involvement of a critical site (e.g., intracranial, intraspinal). To aid in evaluating the relationship of bleeding events to rt-PA administration, they will also be categorized by whether they occurred within 3 days after the initiation of thrombolytic therapy.

Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Ultrasound accelerated thrombolysisEXPERIMENTALPatients in this arm will receive anti-coagulation (intravenous unfractionated heparin) plus the EkoSonic Endovascular System will be used to deliver a low dose \<20mg rt-PA (Actilyse) directly into the occlusive pulmonary thrombus.
Intravenous unfractionated heparinACTIVE_COMPARATORPatients in this arm will receive the standard of care: intravenous unfractionated heparin used as anti-coagulation treatment.
Interventions
NameTypeDescription
EkoSonic Endovascular SystemDEVICEThe EkoSonic Endovascular System will be used to deliver \< 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
Unfractionated heparinDRUGIntravenous unfractionated heparin used for anticoagulation treatment
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 80 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: * Patients with acute PE symptoms \< 14 days. * Filling defect by contrast-enhanced chest CT in at least one main or proximal lower lobe pulmonary artery * Right ventricular dysfunction confirmed by echocardiography where the RV/LV end diastolic diameter ratio is ≥ 1.0. Exclusi...

Countries:GermanySwitzerland
Unlock Eligibility Criteria